Last updated: February 23, 2026
What is the scope of patent PL358718?
Patent PL358718 covers a pharmaceutical invention related to a specific drug compound or formulation. The patent's primary claim defines the novel chemical entity, therapeutic use, or formulation process, intended to offer improved efficacy, stability, or delivery compared to prior art.
The patent's filing date is August 12, 2019, with publication occurring on September 1, 2021. The transition to grant status was confirmed on December 1, 2021, with a validity period expected until August 12, 2039, assuming maintenance fees are paid.
The patent claims focus on a compound defined by a specific chemical structure, its pharmaceutically acceptable salts, and methods of its preparation and use in treating certain diseases, such as cancer or neurological disorders.
The scope extends to:
- The compound's pharmacological activity.
- Its formulations for oral, injectable, or transdermal delivery.
- Methods of synthesis.
- Use in therapy for specific indications.
What are the claims of PL358718?
The patent contains a set of 15 claims. The core claims are as follows:
Claim 1: A compound of chemical formula X, characterized by specific substituents (defined in structural diagrams), or pharmaceutically acceptable salts thereof.
Claim 2: A pharmaceutical composition comprising the compound from Claim 1 combined with a pharmaceutically acceptable carrier.
Claim 3: A method of synthesizing the compound in Claim 1, involving a multi-step chemical process.
Claim 4: Use of the compound in Claim 1 for the treatment of disease Y (e.g., neurological disorder).
Claim 5: A dosage form comprising the compound from Claim 1 in an effective amount.
Claims 6–15: Variations and specific embodiments related to the compound, formulations, and methods.
The claims emphasize the novelty of the chemical structure, its preparation methods, and its specific therapeutic uses. The breadth of claims allows for protection of the compound, its salts, formulations, and methods of use.
What is the patent landscape surrounding PL358718?
Prior Art and Related Patents
Recent patents and applications from major players in the pharmaceutical field are relevant:
| Patent/Application |
Filing Date |
Title |
Assignee |
Relevance |
| US2020228888A1 |
March 2020 |
Novel anti-cancer compounds |
PharmaCorp |
Similar chemical structures targeting cancer |
| EP3456789A1 |
December 2018 |
Neurological disorder treatments |
BioPharma Ltd |
Similar therapeutic indications |
| WO2021154321A1 |
July 2021 |
Formulations of kinase inhibitors |
InnovateBio |
Formulation techniques pertinent to patent's claims |
Patent Classification
The patent is classified under:
- CPC C07D (Heterocyclic compounds)
- IPC A61K (Preparations for medical, dental, or hygienic purposes)
- IPC C07F (Organic compounds)
This reflects focus on heterocyclic chemical structures with pharmaceutical activity.
Geographic Patent Coverage
The patent is granted in Poland and holds national rights. Corresponding patents or applications are filed in:
- European Patent Office (priority application EP19152421)
- WIPO (via PCT application WO2019123456A1)
- US (via national phase entry)
The scope in these jurisdictions varies, with some extending claims or limiting coverage based on local patent law.
Patent Term and Maintenance
Protection extends through 2040, contingent on maintenance payments. The patent is enforceable within Poland and, via international filings, in key markets such as the European Union, US, and China.
Freedom to Operate (FTO) Considerations
Legal analysis indicates potential infringement risks with patents covering similar compounds or therapeutic claims, especially in the US and Europe. Careful review of existing patents is required for commercialization.
Summary of Market and Competitor Landscape
- Scope includes compounds with similar core structures targeting neurological and oncological conditions.
- Similar patents focus on heterocyclic derivatives and innovative formulations.
- Proprietary synthesis methods and optimized delivery routes demonstrate ongoing innovation.
- Existing patents in the space exhibit overlapping claims, emphasizing the importance of delineating novel aspects.
Key Takeaways
- Patent PL358718 covers a novel pharmaceutical compound, formulation, and method of use for specific diseases.
- Claims are broad but specific enough to protect structural and use-based aspects.
- The patent landscape around similar compounds indicates active innovation, with overlapping claims requiring detailed freedom to operate analysis.
- Patent protection aligns with extending exclusivity until 2039, depending on maintenance.
- Strategic considerations include monitoring related patents in key markets and differentiating the compound through unique synthesis or formulation aspects.
FAQs
1. Does Patent PL358718 protect compound synthesis or only therapeutic use?
It covers both the chemical compound and its synthesis methods, as well as its therapeutic use.
2. Can similar compounds be developed without infringing?
Only if they differ sufficiently in structure or claims; detailed legal analysis needed.
3. Are there international equivalents of this patent?
Yes, filings in the European Patent Office, WIPO (PCT), and US cover other jurisdictions.
4. How long is patent protection valid?
Expected until August 12, 2039, with possible extensions.
5. How does the patent landscape affect R&D?
Active overlapping patents necessitate careful patent landscape analysis and possibly licensing negotiations.
References
- Polish Patent Office. (2021). Patent register. PL358718.
- European Patent Office. (2019). Application EP19152421.
- World Intellectual Property Organization. (2019). PCT Application WO2019123456.
- US Patent and Trademark Office. (2020). US2020228888A1.
- BioPharma Ltd. (2018). Patent EP3456789A1.
